Health care giant Johnson & Johnson (NYSE: JNJ) reported second-quarter earnings this morning, posting adjusted earnings per share (EPS) of $1.30 on revenue of $16.5 billion. The consensus estimate from analysts called for EPS of $1.29 on revenue of $16.7 billion. Including one-time charges related to acquisition costs, litigation and other charges, J&J posted EPS of $0.50. Currency exchange rates lowered quarterly revenue by 4.2%.
The worse news from J&J is that the company cut its full-year adjusted EPS forecast from a range of $5.07 to $5.17 to one of $5.00 to $5.07. The revised guidance “reflects the negative impact of recent currency movements, partially offset by the positive contribution from the Synthes acquisition.” J&J’s $19.7 billion purchase of orthopedic device maker Synthes closed in the second quarter.
The effect of a stronger dollar hit J&J hard, costing the company’s consumer division 5.2% of revenue, and international sales a negative impact of 8%. Currency impacts also hit the medical devices and diagnostics group, lowering global sales by 3.5% and international sales by 6.2%.
J&J shares are up about 0.3% in pre-market trading at $68.67 in a 52-week range of $59.08 to $68.74.
Paul Ausick
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
